StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Lutathera (lutetium Lu 177 dotatate by Quarter

Lutathera (lutetium Lu 177 dotatate — radioligand therapy for neuroendocrine tumors GEP-NETs) ($M)

QuarterlyAnnual

Novartis Lutathera (lutetium Lu 177 dotatate: $219M in Q3 2026, up 2.8% from a year earlier.

Latest, Q3 2026
219
Period ended Sep 30, 2026
Change on a year earlier
+2.8%
213 in Q3 2025
History
35 quarters
Since Q4 2017
Sources
27
Documents cited below

Where the Q3 2026 figure comes from

“|| Lutathera | 219 | 213 | 3 | 3”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLutathera (lutetium Lu 177 dotatate — radioligand therapy for neuroendocrine tumors GEP-NETs) ($M)Year on yearSource
Q3 2026Sep 30, 2026219+2.8%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026225+8.7%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026211+9.3%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025203+6.8%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025213+12.1%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 2025207+18.3%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025193+14.2%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 2024190+29.3%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 2024190+19.5%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 2024175+16.7%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 2024169+13.4%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 2023147+14.8%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 2023159+20.5%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 2023150+74.4%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 2023149+19.2%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022128+11.3%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up lutathera (lutetium Lu 177 dotatate

Cite this data

StockData. (2026). Novartis Lutathera (lutetium Lu 177 dotatate ($M), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-lutathera

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.